Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with Non-Small Cell Lung Cancer

Radiation Oncology

Volumn 2, Issue 1, 2007, Pages

  Uitterhoeve, Apollonia L J ^a   Koolen, Mia G J ^a   van Os, Rob M ^a   Koedooder, Kees ^a   van de Kar, Marlou ^a   Pieters, Bradley R ^a   Koning, Caro C E ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; RADIOMETRY; RECURRENT DISEASE; TIME; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIOMETRY; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548009604     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-2-27     Document Type: Article

References (60)

1. Bray F Tyczynski JE Parkin DM Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries Eur J Cancer 2004 40 96-125 10.1016/j.ejca.2003.08.005 14687795
2. Janssen-Heijnen ML Gatta G Forman D Capocaccia R Coebergh JW Variation in survival of patients with lung cancer in Europe, 1985-1989. EUROCARE Working Group Eur J Cancer 1998 34 2191-2196 10.1016/ S0959-8049(98)00312-8
3. Jemal A Siegel R Ward E Murray T Xu J Smigal C Thun MJ Cancer statistics, 2006 CA Cancer J Clin 2006 56 106-130 16514137
4. Schaake-Koning C W. B Dalesio O Festen J Hoogenhout J van HP Kirkpatrick A Koolen M Maat B Nijs A. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer N Engl J Med 1992 326 524-530 1310160
5. Schuster-Uitterhoeve AL Hulshof MC D. GG Koolen M Sminia P Feasibility of curative radiotherapy with a concomitant boost technique in 33 patients with non-small cell lung cancer (NSCLC) Radiother Oncol 1993 28 247-251 10.1016/0167-8140(93)90065-G 8256003
6. Schuster-Uitterhoeve AL Vaart Schaake-Koning CC Benraadt J Koolen MG Gonzalez GD Bartelink H Feasibility of escalating daily doses of cisplatin in combination with accelerated radiotherapy in non-small cell lung cancer Eur J Cancer 1996 32A 1314-1319 10.1016/0959-8049(96)00077-9 8869092
7. Uitterhoeve AL Belderbos JS Koolen MG van der Vaart P Rodrigus PT Benraadt J Koning CC D. GG Bartelink H Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: Results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer Eur J Cancer 2000 36 592-600 10.1016/S0959-8049(99)00315-9 10738123
8. Belderbos J Uitterhoeve L N. Z Belderbos H Rodrigus P van V Price A van WN Legrand C Dussenne S Bartelink H Giaccone G Koning C Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973) Eur J Cancer 2007 43 114-121 10.1016/j.ejca.2006.09.005 17084621
9. TNM Classification of malignant tumours New York, Wiley-Liss 2002
10. Kwa SL Lebesque JV Theuws JC Marks LB Munley MT Bentel G Oetzel D Spahn U Graham MV Drzymala RE Purdy JA Lichter AS Martel MK Ten Haken RK Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients Int J Radiat Oncol Biol Phys 1998 42 1-9 10.1016/S0360-3016(98)00196-5 9747813
11. ICRU BMD Prescribing, recording and reporting photon beam therapy ICRU report 62 1999
12. Cox JD Stetz J Pajak TF Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 1995 31 1341-1346 10.1016/0360-3016(95)00060-C 7713792
13. Kaplan EL Meier P Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53 457-481 10.2307/2281868
14. Albain KS Crowley JJ Turrisi AT III Gandara DR Farrar WB Clark JI Beasley KR Livingston RB Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group phase II study, SWOG 9019 J Clin Oncol 2002 20 3454-3460 10.1200/JCO.2002.03.055 12177106
15. Curran W Scott C Langer C Phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer. Initial report of Radiation Therapy Oncology Group (RTOG) 9410 Proc Am Soc Clin Oncol 2000 19 484a abstract 1891
16. Curran W Scott C Langer C Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III nsclc: RTOG 9410 Proc Am Soc Clin Oncol 2003 22 621
17. Fournel P Robinet G Thomas P Souquet PJ Lena H Vergnenegre A Delhoume JY Le TJ Silvani JA Dansin E Bozonnat MC Daures JP Mornex F Perol M Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study J Clin Oncol 2005 23 5910-5917 10.1200/JCO.2005.03.070 16087956
18. Furuse K Fukuoka M Kawahara M Nishikawa H Takada Y Kudoh S Katagami N Ariyoshi Y Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 1999 17 2692-2699 10561343
19. Martel MK Ten Haken RK Hazuka MB Kessler ML Strawderman M Turrisi AT Lawrence TS Fraass BA Lichter AS Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients Lung Cancer 1999 24 31-37 10.1016/S0169-5002(99)00019-7 10403692
20. Sause W Kolesar P IV TS Johnson D Livingston R Komaki R Emami B Curran W Jr. Byhardt R Dar AR Turrisi A III Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group Chest 2000 117 358-364 10.1378/chest.117.2.358 10669675
21. Socinski MA Zhang C Herndon JE Dillman RO Clamon G Vokes E Akerley W Crawford J Perry MC Seagren SL Green MR Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity Ann Oncol 2004 15 1033-1041 10.1093/annonc/mdh282 15205196
22. Zatloukal P Petruzelka L Zemanova M Havel L Janku F Judas L Kubik A Krepela E Fiala P Pecen L Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study Lung Cancer 2004 46 87-98 10.1016/ j.lungcan.2004.03.004 15364136
23. Movsas B Scott C Sause W Byhardt R Komaki R Cox J Johnson D Lawton C Dar AR Wasserman T Roach M Lee JS Andras E The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies Int J Radiat Oncol Biol Phys 1999 45 1143-1149 10.1016/ S0360-3016(99)00325-9 10613306
24. Rowell NP O'Rourke NP Concurrent chemoradiotherapy in non-small cell lung cancer (Review) The Cochrane Library Wiley 2005 1 1-37
25. Vokes EE Optimal therapy for unresectable stage III non-small-cell lung cancer J Clin Oncol 2005 23 5853-5855 10.1200/JCO.2005.95.028 16087940
26. Belani CP Choy H Bonomi P Scott C Travis P Haluschak J Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol J Clin Oncol 2005 23 5883-5891 10.1200/JCO.2005.55.405 16087941
27. Auperin A Le PC Pignon JP Koning C Jeremic B Clamon G Einhorn L Ball D Trovo MG Groen HJ Bonner JA T. LC Arriagada R Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients Ann Oncol 2006 17 473-483 10.1093/ annonc/mdj117 16500915
28. Ball D Bishop J Smith J O'Brien P Davis S Ryan G Olver I Toner G Walker Q Joseph D A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: Final report of an Australian multi-centre trial Radiother Oncol 1999 52 129-136 10.1016/ S0167-8140(99)00093-6 10577698
29. Clamon G Herndon J Cooper R Chang AY Rosenman J Green MR Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group J Clin Oncol 1999 17 4-11 10458211
30. Gervais R Ducolone A Le Chevalier T et.al. Conventional radiation (RT) with daily carboplatin (Cb) compared to RT alone after induction chemotherapy (ICT). (vinorelbine (Vt)-cisplatin (p): Final results of a randomized phase III trial in stage III unresectable non small cell lung (NSCLC) cancer. J Clin Oncol 2005 23 16S
31. Groen HJ van der Leest AH Fokkema E Timmer PR Nossent GD Smit WJ Nabers J Hoekstra HJ Hermans J Otter R van Putten JW de Vries EG Mulder NH Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: A multicenter phase III study Ann Oncol 2004 15 427-432 10.1093/annonc/mdh100 14998844
32. Huber R Schmidt M Flentje M et.al. Induction chemotherapy and following simultaneous radio/chemotherapy versus induction chemotherapy and radiotherapy alone in operable NSCLC (stage IIIA/IIIB) Proc Am Soc Oncol 2003 22:22a
33. Jeremic B Shibamoto Y Acimovic L Djuric L Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer J Clin Oncol 1995 13 452-458 7844608
34. Jeremic B Shibamoto Y Acimovic L Milisavljevic S Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/ etoposide for stage III non-small-cell lung cancer: A randomized study J Clin Oncol 1996 14 1065-1070 8648358
35. Janssen-Heijnen ML Smulders S Lemmens VE Smeenk FW van Geffen HJ Coebergh JW Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer Thorax 2004 59 602-607 10.1136/thx.2003.018044 15223870
36. Schild SE Wong WW Vora SA Halyard MY Northfelt DW Kogut HL Wheeler RH The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2005 62 1432-1437 10.1016/j.ijrobp.2005.01.003 16029804
37. Werner-Wasik M Scott C Cox JD Sause WT Byhardt RW Asbell S Russell A Komaki R Lee JS Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): Identification of five groups with different survival Int J Radiat Oncol Biol Phys 2000 48 1475-1482 10.1016/S0360-3016(00)00801-4 11121651
38. Sedrakyan A J. M O'Byrne K Prendiville J Hill J Treasure T Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis J Thorac Cardiovasc Surg 2004 128 414-419 10.1016/ j.jtcvs.2004.04.027 15354101
39. The International Adjuvant Lung Cancer Collaborative Trial Group Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer N Engl J Med 2004 350 351-360 10.1056/NEJMoa031644 14736927
40. Winton T Livingston R Johnson D Rigas J Johnston M Butts C Cormier Y Goss G Inculet R Vallieres E Fry W Bethune D Ayoub J Ding K Seymour L Graham B Tsao MS Gandara D Kesler K Demmy T Shepherd F Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 2005 352 2589-2597 10.1056/NEJMoa043623 15972865
41. Vergnenegre A Daniel C Lena H Fournel P Kleisbauer JP Le CH Letreut J Paillotin D Perol M Bouchaert E Preux PM Robinet G Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC) Lung Cancer 2005 47 395-404 10.1016/j.lungcan.2004.08.010 15713523
42. Vokes E Herndon J Kelley M et al. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): initial analysis of a randomized phase III trial Proc Am Soc Oncol 2004 22 618S: Abstract 2007
43. Keene KS Harman EM Knauf DG McCarley D Zlotecki RA Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer Am J Clin Oncol 2005 28 217-222 10.1097/01.coc.0000145986.78542.44 15923791
44. Saunders M Dische S Barrett A Harvey A Griffiths G Palmar M Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial. CHART Steering committee Radiother Oncol 1999 52 137-148 10.1016/S0167-8140(99)00087-0 10577699
45. Belani CP Wang W Johnson DH Wagner H Schiller J Veeder M Mehta M Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer J Clin Oncol 2005 23 3760-3767 10.1200/JCO.2005.09.108 15837967
46. El Sharouni SY Kal HB Battermann JJ Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy Br J Cancer 2003 89 2184-2189 10.1038/sj.bjc.6601418 14676792
47. Machtay M Hsu C Komaki R Sause WT Swann RS Langer CJ Byhardt RW Curran WJ Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience Int J Radiat Oncol Biol Phys 2005 63 667-671 10.1016/j.ijrobp.2005.03.037 15927409
48. Jeremic B Milicic B Acimovic L Milisavljevic S Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study J Clin Oncol 2005 23 6873-6880 10.1200/JCO.2005.22.319 16192579
49. Jeremic B Milicic B Dagovic A Aleksandrovic J Milisavljevic S Interfraction interval in patients with stage III non-small-cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy: Final results in 536 patients Am J Clin Oncol 2004 27 616-625 10.1097/01.coc.0000138964.98445.c4 15577441
50. Belderbos JS Heemsbergen WD K. DJ Baas P Lebesque JV Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy Int J Radiat Oncol Biol Phys 2006 66 126-134 10.1016/j.ijrobp.2006.04.034 16904518
51. Bradley J Graham MV Winter K Purdy JA Komaki R Roa WH Ryu JK Bosch W Emami B Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma Int J Radiat Oncol Biol Phys 2005 61 318-328 10.1016/j.ijrobp.2004.06.260 15667949
52. Kong FM Ten Haken RK Schipper MJ Sullivan MA Chen M Lopez C Kalemkerian GP Hayman JA High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: Long-term results of a radiation dose escalation study Int J Radiat Oncol Biol Phys 2005 63 324-333 10.1016/j.ijrobp.2005.02.010 16168827
53. H O T A Stereotactic hypofractionation high dose irradiation for stage I Nonsmall cell lung carcinoma Cancer 2004 101 1623-1631 10.1002/ cncr.20539 15378503
54. Belderbos J Heemsbergen W Hoogeman M Pengel K Rossi M Lebesque J Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy Radiother Oncol 2005 75 157-164 10.1016/ j.radonc.2005.03.021 15890421
55. Ahn SJ Kahn D Zhou S Yu X Hollis D Shafman TD Marks LB Dosimetric and clinical predictors for radiation-induced esophageal injury Int J Radiat Oncol Biol Phys 2005 61 335-347 10.1016/j.ijrobp.2004.06.014 15667951
56. Singh AK Lockett MA Bradley JD Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy Int J Radiat Oncol Biol Phys 2003 55 337-341 10.1016/S0360-3016(02)03937-8 12527046
57. Takeda K Nemoto K Saito H Ogawa Y Takai Y Yamada S Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy Int J Radiat Oncol Biol Phys 2005 62 626-629 10.1016/ j.ijrobp.2005.04.004 15936536
58. D. DR Wanders S Minken A Lumens A Schiffelers J Stultiens C Halders S Boersma L Baardwijk A Verschueren T Hochstenbag M Snoep G Wouters B Nijsten S Bentzen SM Kroonenburgh M Ollers M Lambin P Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: A planning study Radiother Oncol 2005 77 5-10 10.1016/j.radonc.2005.06.014 16019093
59. Bonner JA Harari PM Giralt J Azarnia N Shin DM Cohen RB Jones CU Sur R Raben D Jassem J Ove R Kies MS Baselga J Youssoufian H Amellal N Rowinsky EK Ang KK Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 2006 354 567-578 10.1056/ NEJMoa053422 16467544
60. Pfister DG Su YB Kraus DH Wolden SL Lis E Aliff TB Zahalsky AJ Lake S Needle MN Shaha AR Shah JP Zelefsky MJ Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm Journal of Clinical Oncology 2006 24 1072-1078 10.1200/JCO.2004.00.1792 16505426